Literature DB >> 6639194

Management of patent ductus arteriosus in the premature infant: indomethacin versus ligation.

C Mavroudis, L N Cook, J W Fleischaker, H S Nagaraj, R J Shott, W R Howe, L A Gray.   

Abstract

A previous report from our institution analyzed the results of pharmacological (indomethacin) closure of patent ductus arteriosus (PDA) in 82 neonates. Closure was achieved in 54 patients. However, gastrointestinal complications occurred in 21, necrotizing enterocolitis in 13, and focal perforation in 8. Overall mortality in the indomethacin group was 40%. This paper compares the results of that pharmacological experience with our subsequent surgical experience with 86 low-birth-weight neonates for whom gestational age, size, illness, and mode of diagnosis were comparable. Mean weight at operation for this study was 1.1 kg; mean gestational age was 29.1 weeks. All infants required endotracheal-assisted ventilation for severe radiographic and clinical hyaline membrane disease. Range-gated Doppler study, retrograde flush aortography, and echocardiographic measurement of the ratio between the left atrium and the aortic root were used to confirm the diagnosis of PDA. Ligation was done in the neonatal intensive care unit using local anesthesia supplemented with morphine. Ventilation was controlled by an inhalation therapist; drug and blood administration were controlled by the infant's nurse. Surgical ligation was employed in all infants except for 7 in whom hemoclip ductal closure was chosen because of extreme instability, coagulopathy, or ductal perforation. There were no operative deaths. Surgical morbidity included ductal perforation (2 patients), wound infection (1), and phrenic nerve injury (1). Necrotizing enterocolitis occurred in 9 patients. The overall mortality was 17%. Patients with preoperative pneumo-thorax had a 32% overall mortality.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6639194     DOI: 10.1016/s0003-4975(10)60686-8

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  8 in total

1.  Diaphragmatic paralysis among very low birth weight infants following ligation for patent ductus arteriosus.

Authors:  Kai-Hsiang Hsu; Ming-Chou Chiang; Reyin Lien; Jaw-Ji Chu; Yu-Sheng Chang; Shih-Ming Chu; Kin-Sun Wong; Peng-Hong Yang
Journal:  Eur J Pediatr       Date:  2012-07-05       Impact factor: 3.183

2.  Patent ductus arteriosus therapy: impact on neonatal and 18-month outcome.

Authors:  Juliette C Madan; Douglas Kendrick; James I Hagadorn; Ivan D Frantz
Journal:  Pediatrics       Date:  2009-02       Impact factor: 7.124

3.  Increased risk of necrotizing enterocolitis in premature infants with patent ductus arteriosus treated with indomethacin.

Authors:  J L Grosfeld; M Chaet; F Molinari; W Engle; S A Engum; K W West; F J Rescorla; L R Scherer
Journal:  Ann Surg       Date:  1996-09       Impact factor: 12.969

Review 4.  Forty-six years of patient ductus arteriosus division at Children's Memorial Hospital of Chicago. Standards for comparison.

Authors:  C Mavroudis; C L Backer; M Gevitz
Journal:  Ann Surg       Date:  1994-09       Impact factor: 12.969

5.  Multiple courses of indomethacin and neonatal outcomes in premature infants.

Authors:  Madhavi Sangem; Sumita Asthana; Sanjiv Amin
Journal:  Pediatr Cardiol       Date:  2007-12-18       Impact factor: 1.655

6.  Patent ductus arteriosus in premature infants.

Authors:  P K Ghosh; J Lubliner; M Mogilner; V Yakirevich; B A Vidne
Journal:  Tex Heart Inst J       Date:  1986-03

7.  Ligation of patent ductus arteriosus in very low birthweight premature neonates.

Authors:  P K Ghosh; J Lubliner; M Mogilnar; V Yakirevich; B A Vidne
Journal:  Thorax       Date:  1985-07       Impact factor: 9.139

8.  Timing of surgical ligation and morbidities in very low birth weight infants.

Authors:  YoungAh Youn; Cheong-Jun Moon; Jae-Young Lee; Cheul Lee; In Kyung Sung
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.